Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Clifton-Hadley
Transcriptional Networks Associated With Treatment Failure in Advanced-Stage Hodgkin Lymphoma: Data From the Rathl Trial (Cruk/07/033)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
LONG TERM FOLLOW-UP OF FoRT: A PHASE 3 MULTI-CENTER PROSPECTIVE RANDOMIZED TRIAL OF RADIATION THERAPY FOR FOLLICULAR AND MARGINAL ZONE LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
PET-guided Treatment in Advanced-Stage Hodgkin Lymphoma: Yes but Which One?
Oncotarget
Oncology
Interleukin-10 Gene Polymorphisms Are Associated With Freedom From Treatment Failure for Patients With Hodgkin Lymphoma
Oncologist
Cancer Research
Medicine
Oncology
Interim FDG-PET Does Not Predict Outcome in Advanced-Stage Hodgkin Lymphoma Patients Treated With BEACOPP
British Journal of Haematology
Hematology
Human Germinal Center-Associated Lymphoma Protein Expression Is Associated With Improved Failure-Free Survival in Brazilian Patients With Classical Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cost-Effectiveness and Cost-Utility Analysis of Multiple Treatment Strategies Using Abvd and/or Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Outcomes Associated With the Treatment of Newly Diagnosed Stage Iv Classical Hodgkin Lymphoma in Practice Settings in France, Germany and the United Kingdom
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Examining Rare Side Effects in Pooled Trial Data: Symptomatic Osteonecrosis in Hodgkin Lymphoma
Oncotarget
Oncology
Interim FDG-PET Has No Value in Selecting Patients Who Require Treatment Modification in Both Early- And Advanced-Stage Hodgkin Lymphoma
British Journal of Haematology
Hematology